Related Experiment Video
Updated: May 9, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Intraoperative nodal staging: role of sentinel node technology
1Department of General Thoracic Surgery and Breast and Endocrinological Surgery (Surgery II), Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-Cho, Kita-ku, Okayama 700-8558, Japan. smiyoshi@md.okayama-u.ac.jp
Thoracic Surgery Clinics
|August 13, 2013
Summary
Sentinel lymph node (SLN) biopsy is effective for melanoma and breast cancer staging. However, an ideal tracer for identifying SLNs in lung cancer remains elusive, requiring further research for non-small cell lung cancer patients.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Imaging
Background:
- Sentinel lymph node (SLN) biopsy is a minimally invasive staging method for superficial cancers like melanoma and breast cancer.
- It serves as an alternative to extensive lymph node dissection for early-stage tumors.
- Accurate SLN identification is crucial for precise cancer staging and treatment planning.
Purpose of the Study:
- To review the current status of tracers for sentinel lymph node identification in primary lung cancer.
- To highlight the unmet need for an effective agent in non-small cell lung cancer (NSCLC).
Main Methods:
- Literature review of tracers used for SLN identification in lung cancer.
- Analysis of reported identification and accuracy rates for various agents.
- Comparison with established SLN mapping techniques in other cancer types.
Main Results:
- Various tracers including dyes, radioisotopes, magnetite, and iopamidol have been investigated for SLN identification in lung cancer.
- No single agent has demonstrated consistently high identification and accuracy rates for practical clinical use in NSCLC.
- Current methods fall short of the efficacy seen in other oncological applications.
Conclusions:
- The development of an ideal tracer for SLN biopsy in lung cancer is still pending.
- Further research is essential to identify or develop a reliable agent for accurate SLN mapping in NSCLC patients.
- Improved SLN identification could enhance staging accuracy and guide treatment decisions for lung cancer.
